Iantrek Announces US Commercial Launch of AlloFlo Uveo, First Surgical Treatment Targeting the Uveoscleral Pathway

Iantrek announced the official US commercial launch of AlloFlo Uveo, the first surgical treatment specifically designed to target the uveoscleral pathway.

This milestone follows Iantrek’s $42 million Series C financing round, which the company says will fuel its commercial expansion, surgeon education initiatives, and continued clinical innovation.

According to Iantrek, AlloFlo Uveo marks a significant advancement in glaucoma care by introducing a bio-interventional approach to enhance aqueous outflow through the uveoscleral pathway. Unlike existing devices or microinvasive glaucoma surgery (MIGS) solutions, AlloFlo Uveo is engineered to maintain the patency of a surgically created cleft, thereby preserving long-term outflow and offering an important new tool for both surgeons and patients confronting irreversible vision loss.

“Approximately 2.5 million eyes in the US have undergone previous MIGS procedures, but many are now experiencing waning efficacy,” said Adam Szaronos, CEO of Iantrek. “Our early-release program has surpassed all expectations, validating the large unmet need for uveoscleral enhancement as well as strong surgeon adoption of our AlloFlo Uveo technology. We’re now focused on scaling a world-class commercial organization to meet the growing demand among glaucoma specialists.”

To date, Iantrek has partnered with over 100 surgeons worldwide, resulting in thousands of AlloFlo procedures performed. The procedure’s outcomes and clinical significance have been highlighted in seven peer-reviewed publications.

“As a practicing glaucoma surgeon, I’ve seen firsthand the limitations of existing surgical options,” said Arsham Sheybani, MD, Iantrek Medical Monitor. “AlloFlo Uveo is unique because it provides a minimally invasive, reproducible method for tapping into an underutilized outflow pathway. This is a valuable addition to our surgical armamentarium.”

Spotlight at AAO

Iantrek will highlight AlloFlo Uveo and its growing BIOS portfolio at booth #3501 during this year’s American Academy of Ophthalmology (AAO) meeting. The company said it will celebrate its early clinical adopters and host live discussions and surgical insights from key opinion leaders who participated in the early-release program. Iantrek also invites glaucoma surgeons, innovators, and pioneers to attend a special AAO event hosted by ophthalmologist-comedian Glaucomflecken.